ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2056

Opioids Use Among Medicare Beneficiaries with Knee Osteoarthritis: Prevalence and Correlates of Chronic Use

Elena Losina1, Shuang Song 2 and Jeffrey Katz 3, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital/Harvard Medical School, Boston

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: opioids and Medicare, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Osteoarthritis (OA) of the knee is prevalent among Medicare beneficiaries. Effective pain control is critical for managing this chronic disease. In the last decade, opioids became widely available for persons with knee OA. We sought to identify knee OA patients that use opioids chronically and occasionally, and determine factors associated with greater risk of occasional and chronic opioid use among knee OA patients ≥ 65years of age.

Methods: We used the Medicare Beneficiary Survey (MCBS) of a nationally representative sample of Medicare beneficiaries administered in 2015. MCBS survey data are linked to Medicare claims. We selected a knee OA cohort from community-dwelling MCBS respondents age ≥ 65 who had at least one outpatient visit in Medicare Parts A or B with an ICD-10-CM code of a) M17.9 or b) M25.569 (Pain in unspecified knee) plus M15.x or M19.90. We obtained data on demographics, smoking, marital status, comorbidities and prescribed medications from survey data and claims. We included all prescribed medication records classified as opioids under the First Databank therapeutic analgesics category. We stratified knee OA subjects into three opioid use groups: 1) none, 2) occasional (1-5 prescriptions/year), 3) chronic (6+ prescriptions/year). We built several multivariable logistic regression models to determine independent correlates of any opioid use vs non-use; chronic vs. non-use and chronic vs. occasional use.

Results: We identified a cohort of 620 persons with knee OA. Mean age was 78.5 (SD 7.3), 65% were female. 31% of the cohort had at least one opioid prescription during 2015. 10% of the overall cohort were identified as chronic opioid users, and 21% of the overall cohort as occasional users. Multivariable analyses that compared any opioid use to no use identified several patient features associated with greater risk of opioid use: ≥ 1 fall in the prior year (OR 1.96, 95% CI 1.16-3.30; ≥ 2 comorbidities (OR 2.62, 95% CI: 1.30, 5.29) and use of NSAIDS (OR 3.74, 95% CI: 2.09-6.71). Married beneficiaries had 0.50 odds of using opioids compared to those who were not married (95% 0.30-0.84). When we compared chronic opioid users to no users, features associated with chronic use included low household income (< 30K/annually; OR 6.13, 95% CI: 2.39-15.7; ≥ 2 comorbidities (OR 3.27, 95% CI: 1.25-8.55) and NSAID use (OR 2.77, 95% CI: 1.14-6.71). Comparing chronic users with occasional opioid users, features associated with chronic use included low income (OR 6.15, 95% CI: 2.04-18.44) and current smoking (OR 5.83, 95%CI: 1.15-29.45).

Conclusion: Over 30% of Medicare beneficiaries with knee OA use opioids and 10% use them chronically. Low income, NSAID use and higher burden of comorbidities are associated with greater risk of opioid use, while marriage was associated with lower risk of use. The causal relationship between prior falls, low income and marital status and risk of current opioid use requires further study. Efforts to find non-opioid regimens for knee OA would be especially useful for patients with risk factors identified in this study.


Disclosure: E. Losina, Flexion, 2, Flexion Therapeutics, 2, Pfizer, 2, Pfizer Inc, 2, Regeneron, 5, Regeneron Pharmaceuticals, 5, Roche/Genentech, 2, Samumed, 2, TissueGene, 2, Velocity, 5, Velocity Pharaceutical Development, 5, Velocity Pharmaceutical Development, 5; S. Song, None; J. Katz, Flexion, 2, Flexion Therapeutics, 2, Samumed, 2.

To cite this abstract in AMA style:

Losina E, Song S, Katz J. Opioids Use Among Medicare Beneficiaries with Knee Osteoarthritis: Prevalence and Correlates of Chronic Use [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/opioids-use-among-medicare-beneficiaries-with-knee-osteoarthritis-prevalence-and-correlates-of-chronic-use/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/opioids-use-among-medicare-beneficiaries-with-knee-osteoarthritis-prevalence-and-correlates-of-chronic-use/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology